MRK Merck & Co., Inc. Loading...

From AMGN earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
20:30
Aug 04 ◎
Murdo Gordon Executive Vice President, Global Commercial Operations, Amg… AMGN Q2 FY26 call
Merck's newly approved oral PCSK9 inhibitor has food restrictions and Amgen does not see it as a direct threat, viewing the market as under-penetrated and Repatha's strong efficacy data and injectable compliance as durable advantages. — This challenges the bear thesis that oral PCSK9s will cannibalize the injectable market, indicating potential pricing and share resilience for Repatha.
MRK
HIGH

About MRK Analyst Coverage

Buzzberg tracks MRK (Merck & Co., Inc.) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Murdo Gordon.